New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty
Express News | Tempus Time Network Expands Support of Phase I Clinical Trials to Accelerate Activation and Enrollment
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment
Earnings Preview: Tempus AI to Report Financial Results Post-market on May 06
Tempus AI Publishes XF+ Assay Study Results in Journal of Molecular Diagnostics
Tempus AI Announces Publication Of Its Study 'Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy' In The Journal of Molecular Diagnostics
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Shroomie : no.. it's above the 200 ma now. Just hold
72166072 : MicroStrategy is sending stocks down. it was bad earnings.